-+ 0.00%
-+ 0.00%
-+ 0.00%

AC Immune Q1 net loss narrows 22.2% to CHF 14.8 million

PUBT·04/30/2026 11:13:25
Listen to the news
AC Immune Q1 net loss narrows 22.2% to CHF 14.8 million
  • AC Immune posted a net loss of CHF 14.8 million for Q1 2026, narrowing 22.2%.
  • Revenue rose 13% to CHF 1.12 million.
  • Operating loss improved 23.6% to CHF 14.79 million on lower R&D spending.
  • Cash resources fell to CHF 74.8 million as of March 31, 2026.
  • Pipeline progress included first dosing in a Phase 1 trial of NLRP3 inhibitor ACI-19764, with SAD/MAD results expected in H2 2026.
  • ABATE trial advanced with initiation of final AD4 cohort for ACI-24, triggering a $12 million milestone payment from Takeda.
  • Funding runway was reaffirmed into Q4 2027, excluding potential milestone payments.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AC Immune Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604300705PRIMZONEFULLFEED1001179037) on April 30, 2026, and is solely responsible for the information contained therein.